الفهرس 
Basic AspectsOnly 14 pages are availabe for public view
 |  | from | 257 |  |  |
| | | from | 257 | | |
Abstract
Antiphospholipid syndrome (APS) is an autoimmune thrombophilic condition occurring due to the presence of antibodies that recognize phospholipid binding proteins.
The disease can be primary or secondary. Primary APS occurs in the absence of any other related disease while secondary APS occurs with other autoimmune diseases, such as systemic lupus erythematosus.
We performed a cross sectional study on 70 patients with APS, and they were studied regarding to demographic pattern, clinical manifestations and immunological characteristics and they further subdivided into two groups:
1. Primary APS, including APS patients without associated other autoimmune rheumatic diseases (ARD). They consisted of 17 patients (24.29%).
2. Secondary APS or ARD/APS, including APS patients with associated other ARD. They consisted of 53 patients (75.71%), 52 patients of them (98.1%) were secondary to SLE while 1 patient (1.9%) was secondary to Sjogren`s syndrome.
Venous thrombosis was reported in more than half of our patients while arterial thrombosis was reported in 22.6%. Moreover, thrombocytopenia and livedo reticularis were the most common non criteria clinical manifestations among APS patients.
Additionlly, Obstetric complications occurred in 87.2% of APS married females and late abortion was the most common among them.
Our study showed comparable clinical and laboratory data among patients with PAPS and ARD/APS without significant differences between both groups.
LA, aCL and anti β2GPI were the major antibodies that associate the clinical manifestations of APS and aCL was the most common aPL that detected in our APS patients.
Significant associations were found between LA, anti β2GPI with obstetric complications, arterial thrombosis, thrombocytopenia and livedo reticularis while no significant association was found between aPLs and occurance of venous thrombosis and aPLs at certain cutoff values have an important role for predicting APS related clinical events
.